Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also off… Read more
Sensei Biotherapeutics Inc (SNSE) - Total Liabilities
Latest total liabilities as of September 2025: $4.58 Million USD
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has total liabilities worth $4.58 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sensei Biotherapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Sensei Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sensei Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sena J Property PCL
BK:SENX
|
Thailand | ฿1.82 Billion |
|
Almadex Minerals Ltd
PINK:AAMMF
|
USA | $321.79K |
|
Borealis Exploration Ltd
PINK:BOREF
|
USA | $36.05 Million |
|
Strategic Metals Ltd
PINK:SMDZF
|
USA | $5.94 Million |
|
Luna Innovations Incorporated
NASDAQ:LUNA
|
USA | $70.48 Million |
|
Avant Technologies Inc.
OTCQB:AVAI
|
USA | $2.97 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Sensei Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sensei Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sensei Biotherapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Sensei Biotherapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.97 Million | -26.42% |
| 2023-12-31 | $9.48 Million | -36.67% |
| 2022-12-31 | $14.97 Million | +123.00% |
| 2021-12-31 | $6.71 Million | +21.26% |
| 2020-12-31 | $5.54 Million | -92.08% |
| 2019-12-31 | $69.88 Million | +26.29% |
| 2018-12-31 | $55.33 Million | -- |